Sprint Bioscience (Q1 Interview): Positive pipeline development and increased attention after TREX1 deal
15 maj, 07:15
15 maj, 07:15
We sat down with Johan Emilsson, the CEO of Sprint Bioscience, to discuss the company's Q1 progress, the outlook for its pipeline and the growing attention the company has attracted following the TREX1 licensing deal with Gilead.
15 maj, 07:15
We sat down with Johan Emilsson, the CEO of Sprint Bioscience, to discuss the company's Q1 progress, the outlook for its pipeline and the growing attention the company has attracted following the TREX1 licensing deal with Gilead.
Aktieanalys
Ekholms sorti
Styrräntan
Aktieanalys
Ekholms sorti
Styrräntan
1 DAG %
Senast
OMX Stockholm 30
0,55%
(17:29)
OMX Stockholm 30
1 DAG %
Senast
3 178,64